Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||JNJ-63723283 + Niraparib|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|JNJ-63723283||JNJ63723283|JNJ 63723283|Cetrelimab||Immune Checkpoint Inhibitor 135 PD-L1/PD-1 antibody 80||JNJ-63723283 (Cetrelimab) is a monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 (CD274) ligand, potentially resulting in enhanced anti-tumor immune response (PMID: 28943093).|
|Niraparib||Zejula||MK4827||PARP Inhibitor (Pan) 23||Zejula (niraparib) binds and inhibits PARP, which may result in accumulation of DNA damage and apoptosis of tumor cells (PMID: 23810788). Zejula (niraparib) is FDA-approved as maintenance therapy in patients with recurrent or newly-diagnosed epithelial ovarian, fallopian tube, or primary peritoneal cancer in complete or partial response to platinum-based chemotherapy, and in ovarian, fallopian tube, or primary peritoneal cancer that received 3 or more chemotherapies and is homologous recombination deficient as indicated by either a deleterious or suspected deleterious BRCA mutation, or genomic instability and progressed 6 months or more after response to last platinum-based chemotherapy (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT04592237||Phase II||Niraparib Cabazitaxel + Carboplatin + JNJ-63723283 JNJ-63723283 + Niraparib||Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer||Recruiting||USA||0|
|NCT03431350||Phase Ib/II||JNJ-63723283 + Niraparib||A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer||Active, not recruiting||USA | CAN||5|